Narrow List by Age:
(Refer to Clinical Summary for age requirements)
Protocol | COG ACCL1932 |
---|---|
Cancer Type: | multi-site |
Fast Facts |
COG-ACCL1932: Letermovir Prophylaxis for Cytomegalovirus in Pediatric Hematopoietic Cell Transplantation
Age: ≥2 years and <18 years at the time of enrollment
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | COG AGCT1531 |
---|---|
Cancer Type: | Germ Cell |
Fast Facts |
A Phase III Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors
Age:
Low Risk Stratum (Stage I Ovarian Immature Teratoma and Stage I Malignant GCT (all sites))
Patients must be < 50 Years of Age at Enrollment.
Standard Risk 1
Patient must be < 11 Years of Age at Enrollment.
Standard Risk 2 & AYA-HEARS
Patients must be ≥ 11 and < 25 Years of Age at Enrollment.
Protocol | COG APEC14B1 |
---|---|
Cancer Type: | All patients |
Fast Facts |
The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
Subjects must be ≤ 25 Years of Age at Time of Original Diagnosis, except for Patients who are being Screened Specifically for Eligibility onto a COG (or COG Participating NCTN) Therapeutic Study, for whom there is a Higher Upper Age Limit.
Protocol | COG ALTE03N1 |
---|---|
Cancer Type: | Multi-site Cancer Control |
Fast Facts |
Key Adverse Events After Childhood Cancer
Diagnosis of Primary Cancer at Age 21 or Younger, Irrespective of Current Age.
Protocol | COG ALTE05N1 |
---|---|
Cancer Type: | Multisite Long Term Follow-up |
Fast Facts |
Umbrella Long-Term Follow-Up Protocol
Only Available to Patients Already Enrolled on a COG Intervention Protocol.
Protocol | COG APEC1621 – MATCH Protocol SC |
---|---|
Cancer Type: | Screening |
Fast Facts |
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
Protocol | COG APEC1621 - MATCH Protocol F |
---|---|
Cancer Type: | Molecular |
COG APEC1621F
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase II subprotocol of Ensartinib in patients with tumors harboring ALK or ROS1 genomic alterations
Patients must be ≥ than 12 months and ≤ 21 years of age at the time of study enrollment.
Protocol | COG ACCL21C2 |
---|---|
Cancer Type: | Multi-site Cancer Control |
Fast Facts |
COG-ACCL21C2: Prospective Cohort Study to Evaluate Immunologic Response Following COVID-19 Vaccination in Children, Adolescents and Young Adults with Cancer
≥6 months and ≤37 years of age at time of enrollment
Please check out the rare protocol list to locate other studies within this disease site.
Cancer clinical trials are research studies for developing better ways of detecting,
treating, and eventually preventing cancer. By taking part in a clinical trial,
you are among the first to receive new research treatments before they are widely
available. Your participation in a clinical trial will influence the future direction
of cancer care.
If you are interested in participating in a clinical trial, consult with your physician.
Please note: clinical trials are not risk free. Patients must explore the options
that are best for their individuals needs with the help of their physician.